Far Eastern Memorial Hospital
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups
研究概览
简要总结
To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
详细描述
Women aged 20 and above, diagnosed with advanced stage ovarian cancer (FIGO stage II~IV), who had received debulking surgery, followed by adjuvant chemotherapy (either dose-dense or intraperitoneal) at our institution between 01 January 2006 and 31 December 2018 were included in the study. Patient characteristics, any treatment related side-effects (peri-operative and post-operative complications, chemotherapy related adverse events), treatment response (complete or partial response, stable disease or progressive disease), post-treatment surveillance (disease status: disease-free, recurrence or cancer-related death) will be recorded. Univariate and multivariate logistic regression analysis will be employed to evaluate the survival benefit of the two different chemotherapy methods.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with FIGO stage II~IV ovarian cancer
- •At least one cycle of intravenous dose-dense or intraperitoneal chemotherapy had been administered as the front-line chemotherapy.
排除标准
- 未提供
结局指标
主要结局
Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups
时间窗: 10 years
months
次要结局
- Overall survivals between this two groups(10 years)
研究者
Sheng-Mou Hsiao
Chief of Department of Obstetrics & Gynecology, Associate Professor
Far Eastern Memorial Hospital
